Böll B - Search Results

1

Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.

Haverkamp H, Böll B, Eichenauer DA, Sasse S, Fuchs M, Borchmann P, Diehl V, Engert A, von Tresckow B. Haverkamp H, et al. Among authors: boll b. J Clin Oncol. 2015 Aug 1;33(22):2430-6. doi: 10.1200/JCO.2014.60.4264. Epub 2015 Jun 22. J Clin Oncol. 2015. PMID: 26101245 Clinical Trial.

2

Last Resort Antibiotics Costs and Reimbursement Analysis of Real-Life ICU Patients with Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Germany.

Jeck J, Wingen-Heimann SM, Jakobs F, Franz J, Baltin CT, Kron A, Böll B, Kochanek M, Cornely OA, Kron F. Jeck J, et al. Among authors: boll b. Healthcare (Basel). 2022 Dec 15;10(12):2546. doi: 10.3390/healthcare10122546. Healthcare (Basel). 2022. PMID: 36554068 Free PMC article.

3

The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.

Böll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A, Engert A, Pogge von Strandmann E. Böll B, et al. Blood. 2005 Sep 1;106(5):1839-42. doi: 10.1182/blood-2005-01-0427. Epub 2005 May 5. Blood. 2005. PMID: 15878978 Free article.

4

Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.

Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Böll B, Simhadri VL, Borchmann P, McKinnon PJ, Hallek M, Engert A. Pogge von Strandmann E, et al. Among authors: boll b. Immunity. 2007 Dec;27(6):965-74. doi: 10.1016/j.immuni.2007.10.010. Epub 2007 Dec 6. Immunity. 2007. PMID: 18055229 Free article.

5

Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma.

Rautert R, Schinköthe T, Franklin J, Weihrauch M, Boll B, Pogge E, Bredenfeld H, Engert A, Diehl V, Re D. Rautert R, et al. Among authors: boll b. Leuk Lymphoma. 2008 Nov;49(11):2091-8. doi: 10.1080/10428190802441339. Leuk Lymphoma. 2008. PMID: 19021051

6

Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma.

Reiners KS, Gossmann A, von Strandmann EP, Böll B, Engert A, Borchmann P. Reiners KS, et al. Among authors: boll b. J Immunother. 2009 Jun;32(5):508-12. doi: 10.1097/CJI.0b013e3181a25daf. J Immunother. 2009. PMID: 19609243

7

Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.

Böll B, Eltaib F, Reiners KS, von Tresckow B, Tawadros S, Simhadri VR, Burrows FJ, Lundgren K, Hansen HP, Engert A, von Strandmann EP. Böll B, et al. Clin Cancer Res. 2009 Aug 15;15(16):5108-16. doi: 10.1158/1078-0432.CCR-09-0213. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671844

8

Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma.

Böll B, Borchmann P, Topp MS, Hänel M, Reiners KS, Engert A, Naumann R. Böll B, et al. Br J Haematol. 2010 Feb;148(3):480-2. doi: 10.1111/j.1365-2141.2009.07963.x. Epub 2009 Oct 15. Br J Haematol. 2010. PMID: 19863533 Free article. Clinical Trial. No abstract available.

9

TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.

Vahdat AM, Reiners KS, Simhadri VL, Eichenauer DA, Böll B, Chalaris A, Simhadri VR, Wiegmann K, Krell HW, Rose-John S, Engert A, von Strandmann EP, Hansen HP. Vahdat AM, et al. Among authors: boll b. Leukemia. 2010 Jan;24(1):51-7. doi: 10.1038/leu.2009.230. Epub 2009 Nov 5. Leukemia. 2010. PMID: 19890373

10

Activity of cetuximab as single agent in a patient with relapsed multiple myeloma.

Böll B, Eichenauer DA, Von Tresckow B, Peine D, Hallek M, Engert A, Hübel K. Böll B, et al. Leuk Lymphoma. 2010 Mar;51(3):562-4. doi: 10.3109/10428190903580428. Leuk Lymphoma. 2010. PMID: 20095962 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

153 results

Search Page

Filters